http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014209246-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c668244125a0418112401b094c9e6b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
filingDate 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35637bc46852a74a14482a19db16af6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0160ec9ed188ad5b3f379cfb7a0b47a2
publicationDate 2014-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2014209246-A1
titleOfInvention Design of terbinafine hydrochloride loaded liposome included pullulan film system for ungual treatment of onychomycosis
abstract Onychomycosis is cured with systemic treatment of terbinafine hydrochloride. But systemic therapy has side effects therefore topical / ungual therapy is needed. The structure of nail plate make difficult topical therapy and decrease effectiveness of treatment. In this study, terbinafin hydrochloride loaded liposome included pullulan film formulation was prepared for ungual treatment of onychomycosis. The lack of adverse effects of systemic treatment and the increase the patient compliance are the main advantages of the planned formulation to the existent formulations.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113262310-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11576870-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2706115-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11319566-B2
priorityDate 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010086723-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280965
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128121089
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395318
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11025495
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439586
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127764382
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1549008
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422749
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282481
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID192826
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421612
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422748
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421611
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127916803
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5402
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423537

Total number of triples: 50.